Exhibit 99.3 Sustainability & P|ESG Report 2024 www.ascendispharma.com

Patients|Environmental, Social and Governance Report (P|ESG) Content Introduction Introduction Progress 03 A message from our Executive Management Team 13 Patients 04 Our Business Model 18 Environmental P|ESG 05 A Brief History 22 Social Approach 07 2024 Sustainability & P|ESG Highlights 28 Governance Ambitions P|ESG Approach Progress 08 Our Sustainability & P|ESG Approach and Reporting 35 2025 Sustainability & P|ESG Ambitions 10 Key Topics 11 P|ESG Risks Ambitions As part of the Ascendis Pharma A/S 2024 Annual Report, this report outlines the Sustainability and what we refer to as Patient, Environmental, Social and Governance (P|ESG) reporting activities for all Ascendis Pharma Group entities. Through this report, we fulfill our compliance with Section 99a (CSR), Section 99b (Gender Diversity) and Section 99d (Data Ethics) of the Danish Financial Statements Act. 2

Introduction P|ESG Approach A message from our Executive Management Team At Ascendis Pharma, we remain dedicated to advancing our TransCon® technology platform as we continue to grow as a biopharmaceutical company with a clear focus on improving patients' lives. Guided by our values and vision, we are determined to fulfill our mission of developing therapies that address unmet medical needs. Progress Our commitment to responsible corporate governance is a key part of our work to deliver safe and effective medicines to those who rely on our products. As we continue to grow, we also recognize that our impact on local and global communities, as well as the environment, is expanding. This ongoing development encourages us to continuously assess and refine our approach to ESG reporting so that Ambitions our P|ESG framework evolves in line with both our growth and the expectations of our stakeholders, and that focus is placed on areas where we can make the most meaningful difference. This report reflects our performance in 2024, as well as our commitment to continue progressing on our P|ESG journey in alignment with current and emerging regulations. We extend our gratitude to all those who have contributed to our efforts and look forward to building on these foundations in the years ahead. 3

Our Business Model Ascendis Pharma was founded in 2007. We are support our research initiatives and clinical France, the UK, and the Nordic countries. Through applying our innovative TransCon platform to trials, and we use Contract Development and exclusive sales and distribution partners covering build a leading, fully integrated, global biopharma Manufacturing Organizations (CDMOs) to more than 50 countries, we now have a global company focused on making a meaningful manufacture finished drug products intended presence and are preparing to support patients difference in patients' lives. Guided by our core for clinical or commercial use. We do not around the world. Introduction values of Patients, Science and Passion, we use manufacture any finished drug products in- our TransCon technologies to create new and house. As a company, we strive to make meaningful potentially best-in-class therapies. improvements in patients' lives. We make We currently have two marketed products, business decisions based on patient needs, and TransCon is a technology platform that uses Skytrofa® and Yorvipath®, and a diversified we do our best every day to realize our products' advanced knowledge of chemistry to overcome portfolio of product candidates in clinical benefits for the patients. We are driven by challenges of developing new therapeutics. It development in endocrinology rare diseases science and data and dedicated to being curious combines known biology with the benefits of and one product candidate in clinical and diligent when innovating, developing and P|ESG prodrug and sustained-release technologies with development in oncology. improving products and processes. Approach the goal of optimizing the therapeutic effect. This could mean enhancing safety, tolerability, efficacy With an expanding global presence, we are Our business model is built on fast, successful and convenience. positioned to reach patients worldwide. In drug development and commercial therapeutic the United States, we have established a synergies. Today, our teams are advancing programs in multifaceted organization to support ongoing endocrinology rare diseases and oncology, and commercialization efforts and serve as a we are also collaborating on the development foundation for future endocrinology rare Progress of product candidates based on TransCon in disease product launches. Similarly, we have other therapeutic areas and markets. We rely expanded our direct presence in Europe by on Contract Research Organizations (CROs) to building integrated organizations, in addition to Germany, in Austria, Switzerland, Spain, Italy, Ambitions 4

2007 A Brief History Ascendis Pharma is established. 2008 TransCon hGH is created. 2009 Transition from pre-clinical to clinical company. 2014 TransCon CNP is created. 2015 U.S. Nasdaq listing. TransCon PTH is created. 2018 Vision 2020 established. Strategic investment and exclusive license agreement with Visen Pharmaceuticals. 2019 Vision 3x3 established. Oncology pipeline announced. 2021 TransCon hGH U.S. approval. Establishment of commercial presence in the U.S. 2022 TransCon hGH EU approval. 2023 TransCon PTH EU approval. Establishment of commercial presence in Germany. 2024 Exclusive license agreement with Teijin Ltd. TransCon PTH US approval. Presence established in Italy, France, Spain, the UK, Austria, Switzerland and the Nordic countries. International sales and distribution partnerships established. Strategic investment and exclusive license agreement with Eyconis, Inc. Novo Nordisk A/S exclusive license agreement.

Global Presence Introduction P|ESG Approach Progress Ambitions Strategic investment and Direct markets Exclusive distribution agreement exclusive license agreement Exclusive license agreement 6

2024 Sustainability & P|ESG Highlights In 2024, we conducted our pilot Double Materiality Assessment and continued improving our methodology in order to align our 2025 reporting with the material impacts, risks and opportunities identified. Introduction Patients Environmental • Launched Yorvipath in Germany and the • Successfully reported on our Scope 1 and 2 emissions data, representing climate U.S. impacts related to on-site energy consumption and purchased electricity and heat. • Launched a Named Patient Program across Europe and International Markets for TransCon PTH. P|ESG Social Approach • Established collaborative relationships with Patient Advocacy groups. • Successfully hired and onboarded 304 employees. • Contracted six new sales and distribution • Continued focus on the attraction and retention of talent. partners covering 50 countries. • Ascendis Employeeship sessions focusing on ownership and collaboration were • Continued activities for Skytrofa conducted throughout the year to emphasize individual self-development and team registries in the United States and performance. initiated support to German registry Progress INSIGHTS-GHT. • Launched the Ascendis Care umbrella brand in Germany for all our patient- Governance centric initiatives, including support materials for patients. • Carried out due diligence on sales and distribution partners. • Launched the Patient Support Program in • Implemented various policies and procedures to support future commercial launches. Germany and Austria for patients under Ambitions • Established an approved supplier list for biological matrices to support high welfare Yorvipath treatment simultaneous to standards for animals used to generate these. market launch. • Signed the Marseille Declaration on the worldwide implementation of high standards • Accepted over 60 participating sites for animals housed and used internally and externally by the industry for scientific across the United States for the U.S. purposes to maintain continuous focus on raising the standards for the welfare of Expanded Access Program for TransCon animals internally, and externally through collaboration with the other signatories. PTH. 7

Our Sustainability & P|ESG Approach Our 2024 Sustainability & P|ESG reporting focuses on four key areas: Patients, Environmental, Social and Governance. It is designed to ensure our environmental and social license to operate through responsible governance practices, ultimately benefiting the business and the patients. Introduction our ongoing commitment to improvement. on the interests of various stakeholders About this Report While some ambitions were not fully met, this and other relevant definitions, which are often The Ascendis Pharma 2024 Sustainability & report emphasizes our focus on transparency different than the concept for U.S. federal P|ESG Report reflects our ongoing commitment and continuous progress in adapting to the securities law purposes. Moreover, certain P|ESG to transparency and accountability as we work ever-changing landscape of our business. We information is based on methodologies or data towards aligning with emerging regulations, appreciate your understanding as we continue that are complex and continue to evolve and thus including the European Union's Corporate to navigate our journey toward corporate are subject to uncertainty or change over time. Sustainability Reporting Directive (CSRD) and responsibility. P|ESG meeting the expectations of the users of this Approach Method & Disclaimer report and our affected stakeholders. Please note that while some topics discussed This report, included in the Ascendis Pharma A/S in this report are significant, their importance 2024 Annual Report, covers the Sustainability To this end, this year we conducted a pilot should not be interpreted as rising to the level & P|ESG activities across all Ascendis Pharma Double Materiality Assessment (DMA) where we of materiality as defined under U.S. federal Group entities for the year 2024. We use this identified and assessed our potentially material securities laws and regulations. The concept report to comply with Section 99a (CSR), Section impacts, risks and opportunities. The full list of of materiality used in this report, including any 99b (Gender Diversity) and Section 99d (Data topics is not reflected in this report, but we will references to material or materiality , is based Progress Ethics) of the Danish Financial Statements Act. continue improving our methodology to complete our 2025 DMA and report accurately on the topics most material to Ascendis Pharma and our stakeholders. Vision & Values Patients Through careful due diligence of our business, Patient & Caregiver this report highlights our key P|ESG topics, Clinical Trial Diversity Product Safety Access & Affordability Engagement including the key risks we face, as well as Environmental Social Governance our policies, processes and performance. It Ambitions • Climate Impact• Employee Engagement and • Business Conduct & Ethics outlines forward-looking goals across Patients, Development • Partners & Suppliers• Anti-Corruption & -Bribery • Health & Safety Environmental Stewardship, Social Impact, and • Responsible Marketing • Diversity, Equity & Inclusion • Data Governance Responsible Corporate Governance. • People in Value Chain • Animal Welfare • Human Rights Each area includes updates on our progress Due Diligence, Double Materiality toward the ambitions we set last year, reflecting Reporting & Communication 8

P|ESG Governance Board of Directors Sustainability and P|ESG Reporting at Ascendis Pharma is guided by a governance structure that fosters a collaborative and integrated approach Introduction across the organization. The Ethics & Compliance Committee, including members of Executive Management, plays a key role in overseeing Sustainability & P|ESG efforts Audit Committee at a strategic level. With the upcoming CSRD requirements taking P|ESG effect in 2025, the Audit Committee will provide Approach oversight of non-financial reporting processes, including preparedness for future assurance Sustainability requirements. Members of the Executive Ethics & Compliance Committee & Management Team are also engaged in shaping P|ESG Team our approach to identifying and addressing key P|ESG impacts, risks and opportunities. Progress The Sustainability & P|ESG Team drives the agenda across the organization, working collaboratively with relevant business units and subject matter experts to develop and implement ESG Leadership Team the Sustainability & P|ESG Reporting framework. This cross-functional effort supports alignment with organizational priorities and consistent data collection and accurate reporting. Ambitions This governance framework reflects our commitment to advancing Sustainability & P|ESG Business Areas integration throughout Ascendis Pharma while Involved stakeholders from the entire organization preparing for evolving regulatory and stakeholder expectations. 9

Key Topics As part of our ongoing commitment to aligning our reporting with the priorities set out in the Ascendis strategy and by our stakeholders, this year we reassessed our key topics to confirm that they accurately reflect the most pressing issues to both our business and the patients we serve. Improving diversity and inclusion in clinical trials to ensure that the effectiveness and safety of medicines are tested across Clinical T rial Diversity Page 14 various demographic groups. Introduction Maintaining the highest standards in the development, manufacturing and distribution of pharmaceutical products to ensure Product Safety Page 14 their safety, efficacy and consistency. Accecss & Affordability Page 15 Managing the cost of pharmaceutical products and establishing fair pricing strategies while ensuring sustainable operations. Actively involving patients and their caregivers in decision-making processes, clinical trials and healthcare solutions to Patient & Caregiver Engagement Page 15 improve patient-centered care. P|ESG Mitigating the impacts of climate change, including eventually reducing greenhouse gas emissions and promoting Climate Page 19 Approach sustainability in operations and supply chains. Nurturing a workforce that is engaged, skilled and motivated by offering opportunities for professional growth, fostering Employee Engagement & Development Page 23 innovation and promoting a positive workplace culture. Fostering an inclusive workplace culture that values diversity, ensures equal opportunities for all and promotes a sense of Diversity, Equity & Inclusion Page 24 belonging for all employees. Prioritizing the well-being of employees by implementing comprehensive health and safety measures in all aspects of our Progress Health & Safety Page 25 business. Addressing the impact of the operations of Ascendis Pharma on various stakeholders within the value chain, including People in our Value Chain Page 26 suppliers, distributors and local communities. Respecting and upholding fundamental human rights in all business activities and supply chain operations to ensure fair Human Rights Page 26 treatment and ethical conduct. Upholding high standards of ethical behavior and integrity in all aspects of business, including interactions with customers, Business Conduct & Ethics Page 29 competitors and stakeholders. Ambitions Implementing applicable anti-bribery and anti-corruption measures to ensure transparent, ethical and lawful business Anti-Corruption & -Bribery Page 31 practices. Promoting pharmaceutical products in an honest, ethical and responsible manner, adhering to industry standards and Responsible Marketing Page 31 regulations. Ensuring the responsible collection, storage and use of data, while safeguarding the privacy and security of sensitive Data Governance Page 32 information. Animal Welfare Page 33 Ensuring the ethical treatment and welfare of animals involved in research, development and testing processes. 10 Governance Social Environmental Patients

Introduction P|ESG Risks As part of our business model, we are exposed to various environmental, social and governance (ESG) risks. Effectively P|ESG managing these risks, particularly those that could impact our Approach operations, helps us minimize business disruptions and protect the reputation of Ascendis Pharma. For each of these risk areas, we carefully assess their potential impact and work to define appropriate mitigation strategies. In identifying our priority P|ESG risk areas, we align with our Progress Enterprise Risk Management (ERM) framework. Ambitions 11

Risk Description Risk Impact Mitigating Actions At Ascendis Pharma, effective product innovation is central Ineffective innovation management may result in slower We foster product innovation through rigorous research and to our mission of addressing unmet medical needs. A development timelines and reduced availability of vital development efforts. We actively engage with patients, ensuring key risk to our operations and strategic objectives is the treatments, affecting patient outcomes and satisfaction. our innovations are aligned with their best interests, enabling us challenge of managing product innovation effectively. to bring the right solutions to market. Our laboratory operations have the potential to generate Potential negative environmental impacts could result We take steps to comply with applicable environmental Introduction negative environmental impacts. in regulatory non-compliance, environmental damage regulations and standards. In addition, we regularly maintain and harm to our reputation, affecting our credibility as a laboratorial equipment and implement safety plans to minimize responsible corporate citizen. any potential adverse environmental impacts. Our rapid growth relies on attracting and retaining top Inability to attract and retain employees could hinder our We prioritize employee development and well-being, cultivating a talent. The competitive talent landscape poses a risk to our capacity for innovation and our ability to meet strategic dynamic, inclusive workplace. We emphasize equal opportunities, ability to continue scaling with the necessary expertise. objectives, affecting our growth trajectory. talent retention through career development programs and reward employee contributions with responsibilities and advancement opportunities. We moreover offer competitive P|ESG compensation packages, including both short- and long-term Approach incentives. Employee misconduct, such as failure to adhere to Unethical or illegal behavior by employees could lead to We focus on educating all employees about our internal and applicable legislation or ethical codes, could result in legal, civil or criminal penalties, industry sanctions, and damage external business conduct requirements through comprehensive financial and reputational risks for Ascendis Pharma. to our reputation, impacting both Ascendis Pharma and onboarding and ongoing training in our Code of Business those associated with our organization. Conduct & Ethics. Employees with higher risk exposure due to their work responsibilities undergo specialized training to ensure ethical conduct is maintained across the organization. Progress A key risk involves instances of corruption and bribery, Improper marketing practices could lead to legal, We provide all employees training on interactions with HCPs such as improper gifts, interactions or payments to regulatory and reputational consequences, potentially as part of the Code of Business Conduct & Ethics training. Healthcare Professionals (HCPs), Healthcare Organizations jeopardizing our relationships with HCPs, HCOs and Specialized training is furthermore provided to employees who (HCOs) and patients. These could be perceived as attempts patients, as well as our ability to engage with these groups interact directly with HCPs, HCOs, government officials, patients to influence decision-making regarding the use or and market our products effectively. and caregivers. Our compliance framework within the commercial recommendation of our products. organization reinforces our commitment to responsible marketing, maintaining high ethical standards in all interactions. A significant portion of our operations is outsourced Potential non-compliance by suppliers and partners could By maintaining compliance requirements within our contractual to Contract Manufacturing Organizations (CMOs) and result in legal, financial and reputational consequences, agreements, we ensure responsible sourcing and comply with Ambitions Contract Research Organizations (CROs). The risk jeopardizing the reliability of our product supply and our applicable requirements. Additionally, our Whistleblower Hotline associated with these collaborations lies in ensuring that standing in the market. provides a platform for employees and partners to report any our suppliers and partners maintain full compliance with illegal or unethical behavior. applicable laws and regulations. Given that all our manufacturing is outsourced, the While our risk level is low due to most suppliers being in To prevent human rights violations, we engage with employees primary risk lies within our supply chain. Ensuring OECD countries, any breach of human rights standards in regular training and awareness programs and maintain an compliance with human rights standards in our external could damage our reputation, negatively affect our license accessible Whistleblower Hotline for employees and business collaborations is crucial for maintaining our ethical to operate and undermine stakeholder trust. partners to report illegal and unethical behavior. standing. 12 Human Supply Responsible Business Employee Attraction Environmental Patients Rights Chain Marketing Conduct and Retention Impact

Introduction Patients P|ESG Approach Progress Ambitions 13

At the core of our decision-making is our difficult due to the small numbers affected by Product Safety unwavering commitment to addressing the rare diseases. However, our work in this area has At Ascendis Pharma, we put patient safety unmet medical needs of patients. To this end, led us to expand recruitment efforts, allowing first. We diligently adhere to applicable health we are dedicated to unlocking the full potential us to reach patients from a variety of social and safety laws to ensure that our products and benefit of our products. Our patient-centric backgrounds, ethnicities and nationalities to Introduction consistently meet high standards of safety, approach is not only central to our mission and further strengthen the outcomes of our clinical efficacy and quality. core values, but also a guiding principle that trials. shapes everything we do. This commitment We are committed to maintaining patient safety drives us to make a positive, lasting impact Because rare disease patients are frequently by closely monitoring and managing any on patients' lives, from developing safe and seen at centralized treatment centers, we provide adverse events associated with our products and effective medicines to ensuring their responsible support, such as travel expense reimbursement, services. To achieve this, we have established commercialization. to make participation more accessible. a comprehensive Global Safety Database for Additionally, we seek to leverage the close P|ESG collecting and processing adverse event data. We The Patients chapter in this report highlights our relationships Ascendis Pharma has with patient Approach analyze aggregated reports and engage in signal dedication to improving patient outcomes and communities to better understand and address detection to proactively identify potential safety covers the following key areas: their needs and priorities, fostering patient- risks. When risks are detected, they undergo centered trial designs. thorough assessment, and we implement • Clinical Trial Diversity appropriate actions to address them, including • Product Safety We are also committed to exploring decentralized notifying healthcare professionals, regulatory • Access & Affordability clinical trials to further enhance inclusivity. bodies and the public as needed. • Patient & Caregiver Engagement Decentralization strategies, like in-home nurse Progress support, direct-to-patient shipping of study Our safety measures include continuous Additionally, we provide insights into our overall medications, and virtual site visits, allow patients monitoring of reported adverse events with business governance and policies. For more to participate from a distance, reducing barriers regular updates and guidance provided as detailed information, we invite you to explore tied to travel and proximity to trial sites. However, necessary. Additionally, we maintain product our Code of Business Conduct & Ethics, which these models introduce risks and compliance safety through thorough investigations and the includes a range of publicly available policies. considerations that we carefully assess to uphold implementation of corrective and preventative patient safety and data integrity. actions. Pharmacovigilance training is provided Clinical Trial Diversity regularly to both internal teams and external Ambitions Lastly, we recognize that the broader challenge We recognize the important role of diversity partners, reinforcing our commitment to safety. of finding trial sites that serve a diverse range and representation in clinical trials, including in of populations is a global issue that calls for the rare disease area, which in itself presents Through these efforts, we work to protect patient collaborative action between industry and unique challenges and opportunities. Recruiting well-being and equip healthcare professionals national regulatory agencies to improve a meaningful diverse patient population can be with accurate, timely information on the safety inclusivity in clinical research. profile of our products. 14

We adhere to the following quality and safety hypoparathyroidism, providing them with We have diligently augmented our resources to policies and procedures: access to potentially life-changing treatment. prepare for the seamless introduction of new In collaboration with the respective health products to the market in the United States and • Good Clinical Practice (GCP) authorities and trial investigators, this program to other countries. Simultaneously, we have • Good Laboratory Practice (GLP) ensured that patients who have participated redoubled our efforts to reduce access-related Introduction • Good Manufacturing Practice (GMP) in our TransCon PTH clinical trial programs obstacles that continue to challenge both patients • Good Distribution Practice (GDP) could continue treatment while we awaited and healthcare providers. • Good Pharmacovigilance Practice (GVP) reimbursement in the respective countries. • Requirements for the development of Patient & Caregiver Engagement combination products With Yorvipath available in the U.S. since Our commitment to improving lives starts with December, the program is now closed. Our truly understanding the journeys of patients, their For further information and specific policies, commitment to this program underscores our families and caregivers. Their lived experiences kindly see our Code of Business Conduct & relentless pursuit of innovative solutions for rare P|ESG provide invaluable insights that shape how Ethics. diseases and our unwavering support for the Approach we develop, deliver and support innovative patients who rely on us. healthcare solutions. To better connect with these Access & Affordability communities, we engage with patient advocacy Name Patient Program At Ascendis Pharma, we are dedicated to groups, convene advisory panels and conduct As per regulatory approvals of Yorvipath, accelerating the availability of our innovative detailed research so that their voices are reflected physicians across the world have expressed medicines to patients. To this end, over the in our work to achieve our mission of developing great interest in having specific identified course of 2024 we have expanded our resources new and potentially best-in-class therapies that patients immediately treated. In these programs to better accommodate physicians' requests to address unmet medical needs. Progress it is the physicians who drive the process to have Yorvipath made available before launch ensure access for their patients together with approval by the competent authorities in the In 2024, we focused further on fostering their respective healthcare systems. We have respective countries. We aim to help facilitate meaningful relationships with advocacy established the logistics to accommodate those removal of access-related obstacles that could organizations by not only listening to their requests where possible. act as barriers for patients and their healthcare needs but also supporting them to amplify their providers, where possible. impact. By cultivating partnerships and enabling TM Ascendis Signature Access Program collaboration across stakeholder groups, we seek Expanded Access Program In the end of 2024, we added Yorvipath to our to address common challenges and advance Ambitions portfolio of supported products in the United patient-centered initiatives. Since the initiation of the Expanded Access States. This milestone reflects our unwavering Program (EAP) for TransCon PTH investigational dedication to expanding patient access and As we continue to launch our commercial therapy in 2022, we have accepted over 60 delivering innovative solutions to meet the needs products in select European countries, we participating sites across the United States. of patients and healthcare providers. are prioritizing the needs of under-served This robust network was dedicated to communities. These efforts are guided by addressing the unmet needs of patients with a commitment to ethical collaboration, 15

transparency and respect for regulatory and The PSP provides patients with guidance on Follow-up on enrolled patients will continue industry standards. Every interaction with effectively and safely using our treatments, for up to an additional five years from the last patient organizations is grounded in a spirit of covering everything from preparation to correct participating patient enrollment. Over the 10- partnership, aimed at driving real-world outcomes injection techniques. It facilitates the accurate year period, we expect that the data collected and creating lasting value for the communities we conduct of the titration phase and provides will increase the understanding of longer-term Introduction serve. continuous support throughout the treatment benefits/risks, potentially contribute to clinical journey. The program offers detailed guidance guidelines and provide value to multiple Looking ahead, we are dedicated to deepening on the effective and safe use of our treatments, stakeholders. our understanding of patient needs and finding covering all aspects from preparation to correct innovative ways to bridge gaps in care. By staying usage techniques. Central to this support are live This year, Ascendis Pharma began support for aligned with our core values of trust, integrity training sessions, which utilize demonstration the INSIGHTS-GHT patient registry, a prospective and collaboration, we will continue to evolve our devices and are supplemented by visual aids such observational study, and the first cross-product approach to making a meaningful difference in as Instructions for Use, Quick Reference Guides registry study on growth hormone therapy P|ESG healthcare. and training videos. worldwide collecting long-term data. It records Approach extensive experience of everyday treatment Patient Support Program We are furthermore in the process of establishing with long-acting growth hormones, in which compliant PSP in other direct markets to the experience with products such as Skytrofa is also Ascendis Pharma has introduced a Patient benefit of the patients. Through such programs, being gathered. The aim is to learn more about Support Program (PSP) in Germany and Austria Ascendis Pharma aims to empower patients the use of somatropin preparations in routine to address medication adherence challenges and caregivers to overcome practical barriers, clinical practice and to collect data on long-term and support optimal treatment outcomes. This enhancing adherence to prescribed treatments for efficacy and safety, including patient-relevant program was created in response to observed Progress better health outcomes and quality of life. outcomes such as quality of life. difficulties patients face in consistently following prescribed medication routines, particularly at the Patient Registry onset of a new treatment. In 2023, Ascendis Pharma initiated recruitment Research highlights that overcoming practical for a non-interventional observational patient barriers is a key factor in adherence, especially registry, SkybriGHt, recruiting via treating in injectable therapies where the complexity physicians pediatric patients that have been of administration can be a significant hurdle prescribed Skytrofa. The purpose of the registry Ambitions for some patients. Our goal is to increase the is to advance the understanding of Skytrofa in a perceived ease and convenience of using our diverse and larger real-world population. treatments to improve adherence and treatment experience. Recruitment of patients to the registry will continue for up to five years from initiation. 16

2024 and 2025 Sustainability and P|ESG Reporting Ambitions 2024 Ambitions Status Progress in 2024 2025 Ambitions Review the material impacts, Conduct a double materiality assessment We conducted a pilot Double Materiality risks and opportunities related Introduction to identify key patient priorities within Ongoing Assessment (DMA) and continued to our patients as part of our the scope of our Sustainability & P|ESG improving our methodology. 2025 DMA. Reporting framework. Monitor the regulatory Launch in Germany and Austria of a Launched the Patient Support Program in landscape and seek input from Patient Support Program for chronic Germany and Austria for patients under industry peers and patient hypoparathyroidism patients to significantly Achieved Yorvipath treatment simultaneous to market advocacy groups on the improve patient support and treatment launch. developing field of population outcomes. diversity in clinical trials with P|ESG Approach specific focus on rare diseases, Launch an Ascendis Pharma umbrella brand including oncology. overarching our patient-centric initiatives Launched the Ascendis Care umbrella to reflect our values and commitment and brand in Germany for all our patient-centric Establish access pathways Achieved emphasize our dedication to prioritizing initiatives, including support materials for to our entire endocrinology patients and their well-being at the heart of patients. portfolio across the world to all our efforts. patients in need. Supported Patient Listening Program, Add innovative technology Progress maintained Expanded Access Program based on TransCon to the Build the reputation of Ascendis Pharma as with support from patient organizations HCPs' armamentarium, a rare disease industry leader by identifying Achieved to ensure access to qualifying patients, establishing it as the gold patient-centric, multi-stakeholder-inclusive developed diseases state awareness standard of care for treating priorities. campaign and provided financial support to rare endocrine diseases. patient organizations. Champion ethical, meaningful and evidence-driven scientific Conducted a Patient Journey workshop in Advance initiatives within the advocacy Ambitions exchange with HCPs, anchored Germany, initiated compliant engagements environment by listening, learning and in our deep knowledge of Achieved with patient organizations and strengthened leveraging insights to uplift rare disease medical science, to improve relationships with existing advocacy communities. outcomes in individuals with groups. rare diseases. 17

Introduction Environmental P|ESG Approach Progress Ambitions 18

At Ascendis Pharma, we recognize the Climate Impact importance of understanding and managing Our commitment to climate responsibility spans our environmental impact. While we do not across all our operations and the spaces we own manufacturing sites, we collaborate closely occupy. Our office and laboratory spaces, which with Contract Development and Manufacturing Introduction are located in leased facilities, are central to our Organizations (CDMOs), logistics providers and sustainability initiatives. Over the past year, we third-party partners to align with environmental have collected our Scope 1 and 2 emissions data, principles and comply with applicable laws, enabling us to better assess our climate impact. industry standards and internal guidelines. Although we do not own or directly manage While we continue to assess our environmental manufacturing sites, we are diligent in footprint, we are working to better understand measuring our impact. We partner with Contract our impacts in order to identify potential P|ESG Development and Manufacturing Organizations opportunities for future improvements. This Approach (CDMOs), suppliers and third-party entities to approach extends to our research partnerships achieve our objectives. with Contract Research Organizations (CROs) and our broader supply chain. We encourage our In 2024, we continued our efforts to collect partners and suppliers to demonstrate a shared greenhouse gas emissions data from our largest commitment to environmental responsibility. CMOs and logistics providers. This project targets the upstream and downstream value chain of As we grow, we strive to explore opportunities commercially approved products, as we work Progress for greater environmental responsibility across towards disclosing applicable Scope 3 emissions. our supply chain and business activities, while adhering to applicable regulatory standards. Our ongoing efforts in climate responsibility focus on improving data robustness and strengthening This year's Environmental chapter includes our commitment to regulatory compliance. insights on: • Climate Impact Ambitions • Suppliers & Business Partners For more details, please refer to our full Environmental Policy in our Code of Business Conduct & Ethics. 19

Suppliers Energy Unit 2024 Contract Manufacturing Organizations (CMOs) and logistics providers are Energy Consumption vital to our business model, as we outsource all product manufacturing Total energy consumption MWh 5,780 activities. We expect our suppliers to meet the same standards we set for Introduction ourselves, operating with integrity and adhering to all applicable laws, regulations and the principles outlined in the Ascendis Pharma Code of Scope 1 and 2 GHG Emissions Unit 2024 Business Conduct & Ethics. Scope 1 We have completed the second round of supplier questionnaires. Initially, Gross Scope 1 GHG emissions tCO e 62 2 we launched these questionnaires to gather information from our Scope 2 suppliers. This effort was aimed at enhancing our understanding of their Gross location-based Scope 2 GHG emissions tCO e 1,047 2 practices and their impact on the environment. The insights gained from Gross market-based Scope 2 GHG emissions tCO e 672 2 P|ESG these questionnaires have been invaluable and will serve as the foundation Approach for more extensive assessments in the coming years. The second round Total Scope 1 and 2 Total Scope 1 and 2 emissions (location-based) tCO e 1,110 2 has allowed us to delve deeper into specific areas, fostering a more Total Scope 1 and 2 emissions (market-based) tCO e 734 2 comprehensive evaluation of our suppliers' sustainability practices in alignment with CSRD reporting requirements. Accounting principles As we assess potential suppliers, we consider a range of factors, Energy Consumption Energy consumption for our operations is measured based on the usage of electricity, heat, including their approach to ESG. Our key focus remains on deepening our cooling and fuel, with data derived from meter readings and invoices. For new office spaces with understanding of the environmental impacts, risks and opportunities in our Progress leases starting in 2024, we estimated energy consumption by extrapolating the energy usage per commercial supply chain, particularly regarding climate, water, waste and square meter from our Danish office sites, assuming similar usage patterns. For some German office sites, where heating and cooling consumption data was limited, we applied a similar resource management. extrapolation method based on the usage patterns of our German office sites with complete data. Scope 1 Scope 1 emissions comprise direct CO e emissions from sources that are controlled by Ascendis 2 Pharma. Scope 2 Scope 2 emissions comprise CO e emissions from purchased electricity, heat and cooling 2 Ambitions calculated using both the Market-based and Location-based methods from the GHG Protocol. Total Scope 1 and 2 The sum of our CO e emissions for Scope 1 and 2, calculated using both the Market-based and 2 the Location-based methods. Total Energy Consumption The sum of our total energy consumption for Scope 1 and 2 across operations. 20

2024 and 2025 Sustainability and P|ESG Reporting Ambitions 2024 Ambitions Status Progress in 2024 2025 Ambitions Validate and report on our Scope 1 & 2 We have successfully reported on our Scope Achieved greenhouse gas emissions data. 1 & 2 emissions data. Introduction Expand the collection of greenhouse gas emissions data throughout our upstream We continue our efforts to collect and downstream commercial value chain Not greenhouse gas emissions data from our and report on 2023 Scope 3 greenhouse achieved Skytrofa supply chain, as we work towards Review the material gas emissions for our commercial supply disclosing Scope 3 emissions as required. environmental impacts, risks chains. and opportunities within our operations and commercial Conduct a double materiality assessment to We conducted a pilot Double Materiality supply chains as part of our P|ESG Approach identify key environmental priorities within Ongoing Assessment (DMA) and continued 2025 DMA. our operations. improving our methodology. As part of our pilot Double Materiality Identify key environmental impacts, risks In Assessment (DMA), we have identified and opportunities in our commercial supply progress environmental impacts and risks in our chains. commercial supply chains. Progress Ambitions 21

Introduction Social P|ESG Approach Progress Ambitions 22

In 2024, we recruited and onboarded more For further information and specific policies, We invite Ascendis Pharma employees to share than 300 new employees worldwide, reflecting kindly see our Code of Business Conduct & Ethics. their feedback through various surveys, including another year of substantial growth at Ascendis onboarding and offboarding surveys, as well as Pharma. In connection with the divestment of Employee Engagement & Development targeted pulse surveys on topics like remote work our ophthalmology pipeline, 30 employees left satisfaction. Introduction With a diverse team of ambitious talents, our Ascendis Pharma to join Eyconis. As a result of company culture remains dynamic and fast- our expansion, we now have more than 1,000 We also believe that maintaining and attracting an paced. This year, we continued to enhance our highly skilled and dedicated employees working engaged workforce rests on our ability to be an global recruitment process to emphasize not together across functions and locations to attractive and fair employer. This year, we began only professional skills but also team dynamics advance our mission. a project emphasizing pay equity across the and cultural alignment, reinforcing our efforts to organization to assess and act upon any potential attract and retain top talent. Driven by science, we are focused on developing, instances of pay inequity. Our initial analysis innovating and refining products and processes is promising, indicating little to no systemic P|ESG In line with our Leadership Principles, Ascendis that make a meaningful difference in patients' variation in our pay policies towards our female Approach Pharma prioritizes building leadership capabilities lives. Our employees are central to achieving our and male employees. This is only the beginning, across all organizational levels, recognizing this goals, and we prioritize attracting, onboarding however, as we continue our investigation and as key to creating a motivated and engaged and retaining the right talent to support our efforts in the coming year to promote a clear, workforce. To drive this, we continuously conduct ambitions. objective and transparent pay approach. dedicated leadership training for our leaders across the organization, and we continue to We are also committed to conducting our Lastly, at the discretion of our Board of Directors implement our Let's Talk framework, which business with respect for all individuals and upon management's recommendation, promotes quarterly, in-depth conversations Progress connected to Ascendis Pharma, including those employees are eligible to participate in our short- between managers and employees on critical throughout our value chain. We expect our term and long-term incentive programs. topics such as Impact, Growth, Well-Being, and suppliers and business partners to uphold the Collaboration—all of which we view as essential same standards outlined in our Respecting People to employee development and retention. Policy. Furthermore, we have introduced Ascendis Employeeship , a training initiative designed to In this year's report, the Social chapter support employees in taking ownership of their encompasses the following topics: work situation and enhancing collaboration to Ambitions increase impact across the organization. With this • Employee Engagement & Development initiative, we aim to provide all our people with an • Health & Safety opportunity to develop themselves - and, in turn, • Corporate Diversity, Equity & Inclusion Ascendis Pharma. • People in our Value Chain • Human Rights 23

strives for an equal representation of gender, Corporate Diversity, Equal Opportunity Corporate Diversity, Equity & Inclusion with an acceptable range of 40/60 split to either and Non-Discrimination Policy We are committed to building an inclusive gender in compliance with the guidelines issued workplace where every individual can thrive by the Danish Business Authority. The distribution At Ascendis Pharma, we respect and foster and contribute fully. Diversity, equity and is monitored continuously with a formal biannual Introduction corporate diversity and inclusion and we take inclusion are fundamental principles within our evaluation, so that new initiatives can be pride in being an equal opportunity workplace. organization, woven into our culture, policies and discussed and initiated if necessary to ensure We believe that corporate diversity and inclusion daily practices. compliance. As a result of these, we currently among our workforce is critical to our success as a global company. maintain equal gender representation not only Ascendis Pharma is committed to providing at the Board of Directors level but also across all equal opportunities and fair treatment for We are committed to providing equal management levels within our organization. all individuals based strictly on their merits, opportunity and fair treatment to all individuals free from any discrimination based on race, on the basis of merit without discrimination due Aligned with our commitment to being an P|ESG color, religion, national origin, gender identity to race, color, religion, national origin, gender, attractive and fair employer, our reward Approach sexual orientation, age, disability or other or expression, including pregnancy, sexual philosophy focuses on offering a competitive characteristic protected by law. orientation, age, disability, veteran status, or any and equitable compensation structure. other characteristic protected by law. Compensation decisions are guided by role We also prohibit harassment based on these evaluations, individual qualifications, experience, characteristics in any form, whether physical or Focus on diversity is embedded in processes, and performance assessments, promoting fair verbal and whether committed by supervisors, including recruiting, people development, recognition and rewards for our employees. non-supervisory personnel, or non-employees. leadership development and succession planning Harassment may include, but is not limited to, in compliance with applicable guidelines. Progress offensive sexual flirtations, unwanted sexual Reflecting this commitment, we hold a policy advances or propositions, verbal abuse, sexually regarding our Board of Directors, emphasizing or racially degrading words, or the display in the importance of the best qualifications to drive the workplace of sexually suggestive or racially our business. The overall gender diversity in degrading objects or pictures. leadership positions at Ascendis Pharma meets Making Ascendis Pharma a pleasant and the Danish gender diversity requirements. When rewarding place to work, free from any type of defining equal representation, Ascendis Pharma discrimination or harassment, is fundamental. Ambitions Variations may apply to ensure compliance with local legislation. 24

Headcount 2021 2022 2023 2024 Selling, General and Administration* 236 305 354 492 Health and Safety R&D, Commercial Manufacturing 403 492 525 525 At Ascendis Pharma, we prioritize conducting business in a way that protects the health, safety, Total** 639 797 879 1,017 and well-being of our employees, fully adhering Introduction *Selling, General and Administration includes business and corporate development and commercial activities. to all relevant health and safety laws and **All permanent employees, including part-time and excluding temporary employees and student assistants. regulations. Health and safety considerations are a key part of Unit Gender distribution 2021 2022 2023 2024 our daily operations, and we regularly incorporate (%) feedback from both our employees and external Men/ stakeholders to keep our work environment safe Board of Directors 67/33 57/43 60/40 60/40 Women and compliant. P|ESG Men/ Approach Executive Management 67/33 60/40 50/50 56/44 Our local Danish Environment, Health & Safety Women organization (Arbejdsmiljøorganisation) oversees Men/ efforts to maintain and improve workplace safety. Senior Management 68/32 61/39 59/41 63/37 Women Comprised of a Health & Safety Committee and a Health & Safety Group, this team actively Executive Management and Senior Management correspond to Other Management Levels as defined by Section 99b. monitors our processes and makes adjustments as needed to uphold a safe and healthy workplace. Progress Employee turnover 2023 2024 In other countries where we operate, we take Employee turnover ratio 10.9% 14% relevant steps to comply with applicable national and local health and safety requirements, aligning our practices with regional regulations to protect Work-related accidents 2022 2023 2024 our employees globally. Accidents* (total) 20 26 12 Ambitions Accidents resulting in sick-leave/absence 0 1 2 Accidents resulting in loss of life 0 0 0 *An undesired registered event or exposure that gives rise to personal injury. Registered accident data covers permanent, part-time and temporary staff whilst on duty for Ascendis Pharma. The metrics showcased on this page pertain to Group Level data. 25

People in our Value Chain Human Rights Human Rights and Labor Rights Policy As outlined in the Environmental chapter, Our commitment to human rights is grounded in At Ascendis Pharma, we respect human rights our business relies on a network of suppliers internationally recognized standards, including as well as labor rights, and we expect the same responsible for manufacturing our products. We the Universal Declaration of Human Rights from our suppliers and business partners. We Introduction expect these suppliers to adhere to applicable (UNDHR), the International Covenant on Civil and work proactively for a positive and inclusive laws, regulations and principles of integrity in Political Rights (ICCPR) and its second optional work environment that respects the individual their operations. protocol, and the International Covenant on and is free from any form of discrimination Economic, Social, and Cultural Rights (ICESCR). or harassment. In addition, we unequivocally We aim to enhance our understanding of the oppose any form of trafficking in human beings, compulsory labor and child labor. Respecting social impacts, risks and opportunities within Furthermore, we align our commitment with the each employee's integrity and always treating our commercial supply chain. By doing so, we fundamental conventions of the International everyone with respect are key. foster alignment with our broader commitment to Labor Organization (ILO). These conventions are P|ESG ethical practices and uphold high standards in our crucial for protecting the rights of workers and Approach We set high standards on performance collaborations. are integral components of our human rights management, compensation, rewards and approach. development. Our corporate culture is Our focus is on maintaining strong, transparent characterized by our passion and commitment to relationships with suppliers and identifying areas Guided by the UN Guiding Principles, we help people grow. where improvements can align with our values, integrate human rights considerations into our such as compliance with human rights laws, third-party compliance approach. Our objective is We respect the freedom of association and the workplace safety regulations and responsible to ensure that our partners and suppliers uphold effective recognition of the right to collective business practices. This approach reflects applicable human rights standards and principles. bargaining, applicable laws regarding wages, Progress benefits and working hours as well as the our dedication to building a supply chain that promotion of the fair treatment of Ascendis supports ethical and compliant operations. Our Respecting People Policy, including our Pharma employees as well as those in our value comprehensive Human Rights Policy, can be chain. accessed in our Code of Business Conduct & Ethics. This policy reaffirms our commitment to human rights and serves as a key resource for our workforce and all those engaged with our organization. Ambitions 26

2024 and 2025 Sustainability and P|ESG Reporting Ambitions 2024 Ambitions Status Progress in 2024 2025 Ambitions Continued to enhance our global recruitment Introduction process to prioritize not only professional competencies but also team and culture fit. Attraction, onboarding and retention of talent Furthermore, we continue to implement a to ensure we have the right people to deliver on Ongoing structured process for dialogue between our ambitions. employees and managers called Let's Talk which focuses on Impact, Collaboration, Growth and Well-Being. Review the material social impacts, Leadership development is a continued focus risks and opportunities within our area in Ascendis Pharma which we believe is P|ESG operations and commercial supply Approach critical to ensuring a motivated and engaged chains as part of our 2025 DMA. workforce. We provide dedicated training to newly hired or promoted managers. We also Attraction, onboarding and Continuous focus on leadership and conduct continuous leadership training sessions retention of talent to ensure we employeeship development to enable the across the organization and ensure access to have the right people to deliver on Ongoing development, performance and well-being of our dedicated leadership resources for all people our ambitions. people. leaders to support them in their leadership role. Ascendis Employeeship sessions were Continuous focus on leadership also conducted throughout the year focused and employeeship development Progress on ownership and collaboration, emphasizing to enable the development, individual self-development and team performance and well-being of our performance. people. Conduct a double materiality assessment We conducted a pilot Double Materiality Investigation of our pay policies, to identify key social priorities within our Ongoing Assessment (DMA) and continued improving our emphasizing pay equity across the operations. methodology. organization and taking actionable steps towards ensuring a clear, objective and transparent pay As part of our pilot Double Materiality approach. Identify key social risks in our commercial supply Assessment (DMA) we have identified social Achieved Ambitions chains. impacts and risks in our commercial supply chains. Establish and formalize criteria for categorizing the risk level of our CDMOs and conduct due We have assessed risks in our supply chain and In diligence on high-risk CDMOs using self- continue to collect information from our CMOs in progress assessment questionnaires and resources from order to better understand their risk level. the PSCI. 27

Introduction Governance P|ESG Approach Progress Ambitions 28

At Ascendis Pharma, we are committed to associated policies and procedures. Any procedures aligned with these global minimum conducting our business in line with high ethical identified or potential breaches are subject to requirements while incorporating local-specific standards and in accordance with applicable laws, thorough review and investigation, followed by requirements. and Business Conduct & Ethics plays a central appropriate corrective measures. Consequences role in our Sustainability & P|ESG Reporting for employees can range from additional training Oversight of the Compliance Program is led by Introduction framework. to disciplinary actions, including written warnings the Ethics & Compliance Committee, consisting and, if necessary, termination of employment. of Senior Management representatives, including Acting with integrity in everything we do our CEO. In 2024, the Committee held quarterly is paramount to our license to operate as a Business partners are required to comply with meetings to review the general status of the biopharmaceutical company and is one of the the principles of the Code of Business Conduct Compliance Program and to approve proposals enablers of our success. & Ethics. Any identified or potential breaches are aimed at supporting its continuous improvement. subject to thorough review and investigation. In this year's report, the Governance chapter Violations by business partners may result Effective and T ailored Compliance T raining P|ESG encompasses our commitment to integrity, in contract termination and legal actions, as Approach Education, training and re-training are vital covering the following topics: permitted by applicable laws. to cultivating a strong compliance culture. Employees are required to complete various • Business Conduct & Ethics In 2024, the Code of Business Conduct & Ethics compliance training programs tailored to their • Anti-Bribery & -Corruption was reviewed, updated and approved by the roles, addressing specific topics and associated • Responsible Marketing Board of Directors, reflecting our ongoing risks to ensure relevance and effectiveness. • Data Governance commitment to ethical business practices. • Animal welfare In 2024, employees, including new hires, Progress The Ascendis Pharma Compliance Program completed mandatory training in our Code of All specific compliance and ethics policies as well The Compliance Program underpins our Business Conduct & Ethics. The training involved as detailed governance descriptions can be found dedication to maintaining high ethical standards an e-learning and an assessment requiring a in our Code of Business Conduct & Ethics. and ensuring adherence to applicable laws and 100% passing score. For existing employees, this regulations. This Program includes our Code of served as a refresher, while for new employees, it Business Conduct & Ethics Business Conduct & Ethics, the development was part of their onboarding process. The overall The Code of Business Conduct & Ethics outlines and execution of policies and procedures, completion rate for this training was 99%, with our global compliance framework and policies proactive risk identification and mitigation, and the remaining 1% attributed to employees on Ambitions across our entire value chain. It translates our comprehensive training initiatives on various leave or other extenuating circumstances. values into actionable guidelines, ensuring compliance topics. consistent adherence to high standards of In 2025, we will continue enhancing global and business ethics worldwide. The Compliance Program sets out the minimum affiliate-specific policies and training to support requirements throughout the entire Ascendis employees in making ethical decisions that align Employees are required to comply with the Pharma organization. Each affiliate is in the with applicable laws, regulations and industry Code of Business Conduct & Ethics and its process of establishing compliance policies and standards. 29

Speak Up Policy & Whistleblower Hotline Our policy strictly prohibits retaliation against any Whistleblower Hotline Policy employee who, in good faith, seeks assistance or At Ascendis Pharma, we actively encourage reports suspected misconduct. The Whistleblower Hotline offers employees and expect our employees to voice concerns and externals, e.g., former or potential about unethical behavior or potential and actual To uphold our commitment to transparency employees, members of the Board of Directors, Introduction misconduct related to the Code of Business consultants and third parties, the possibility and accountability, we share key insights into Conduct & Ethics, as well as associated policies to report concerns through a safe channel. In the outcomes of the Speak Up Policy and and procedures. the system you can communicate directly with Whistleblower Hotline over the past four years. the investigation team, and it is possible to be These figures underscore our dedication to We recognize that reporting misconduct to a anonymous. creating a safe environment where employees direct manager may not always feel comfortable, can confidently raise concerns without fear of despite our commitment to fostering open and The Whistleblower Hotline is available 24/7, and retribution. serious concerns can be filed as a written report transparent communication. In such instances, via a secure web form or alternatively via a call P|ESG employees are encouraged to reach out Our Whistleblower Hotline can be accessed 24/7 Approach through the secure hotline. confidentially to HR or Compliance. Additionally, through our website. we provide a Whistleblower Hotline, which allows No retaliation of good faith reporters. for anonymous reporting of concerns. The hotline Third-Party Compliance is accessible to anyone who suspects or has Ascendis Pharma does not accept retaliation At Ascendis Pharma, our dedication to knowledge of a potential or actual violation of our against employees who, in good faith, seek help responsible business conduct extends to our Code of Business Conduct & Ethics, applicable or report concerns or violations. Any reprisal partnerships. We expect all partners to uphold laws, regulations, or internal policies. or retaliation against reporters will be subject the same ethical standards that guide our own Progress to disciplinary action, including potential operations. To this end, we perform relevant due termination of employment. diligence on our sales and distribution partners to ensure compliance with our ethical and legal We will protect your confidentiality in alignment Whistleblower Hotline Reports with applicable laws. If an employee knowingly expectations. makes false reports, this is considered a very serious offense and can warrant disciplinary 2024 0 actions. 2023 0 Ambitions 2022 1 2021 2 30

established processes for reviewing external Anti-Corruption & -Bribery Policy Anti-Corruption & -Bribery medical and promotional materials prior to their As part of the Ascendis Pharma Compliance use. In 2024, these processes were updated to The Ascendis Pharma Anti-Corruption Program, all employees undergo annual training & -Bribery Policy prohibits all forms of align with the evolving global and direct market in the Anti-Corruption & Bribery Policy, which corruption, bribery and kickbacks, whether structure and product reach of Ascendis Pharma. Introduction outlines the expected behavior as representatives they involve a government official or a person of the company. Due to the nature of our or company within the private sector, or they Our ongoing commitment supports our marketing business, we have not identified high actual risks are carried out directly or indirectly through activities to deliver up-to-date, equitable, precise, in relation to corruption and bribery. However a third party. Under this policy, employees impartial and comprehensive information about are strictly forbidden from offering, paying employees with the potential of exposure our products, fostering trust and transparency or authorizing payments to influence the to corruption and bribery risks, such as field across all markets. actions of government officials or healthcare personnel, receive specialized training tailored to professionals, seek preferential treatment their specific challenges. Transparent Interactions or express gratitude for favorable actions. P|ESG Approach Similarly, employees cannot solicit or accept Collaborating with healthcare professionals, To address and monitor potential incidents, the any form of payment or valuable item intended healthcare organizations and patients is a Whistleblower Hotline is available for anonymous to sway their responsibilities or express fundamental aspect of our mission to develop reporting of corruption or bribery concerns. In gratitude for acting in a way that improperly innovative technologies and products that benefit 2024, no incidents were reported. benefited that person. patients worldwide. Looking ahead to 2025, we will continue to refine Indirect payments made through third parties At Ascendis Pharma, our interactions with these our policies and training programs to ensure that would otherwise be impermissible if made stakeholders are always guided by legitimate directly by Ascendis Pharma are also strictly alignment with our risk profile as well as the Progress purposes and conducted in full compliance with prohibited. latest requirements across relevant markets. the applicable regulations governing the Ascendis This policy underscores our commitment Pharma entity, the participants and the location of Responsible Marketing to transparency, integrity and adherence to the interaction. Promotional Review & Compliance ethical standards and legal requirements in all interactions. For more details, please refer Responsible marketing is a cornerstone of the We are deeply committed to transparency in all to the Anti-Corruption & -Bribery Policy in our operations of Ascendis Pharma, and it is therefore our interactions, and we report transfers of value Code of Business Conduct & Ethics. important that all information disseminated about provided to healthcare professionals, healthcare Ambitions products with marketing authorization complies organizations and patient organizations with stringent regulatory standards and ethical in accordance with legal and regulatory practices at all times. requirements. Our marketing activities are conducted in alignment with applicable laws, regulations, and internal guidelines. To support this, we have 31

Data Ethics Policy Data Privacy Data Governance With the evolving landscape of data privacy laws Data Ethics We recognize the fact that our utilization of data, and regulations worldwide, we remain committed whether it is personal or non-personal, can As an innovative biopharma company focused to respecting and protecting personal data across introduce potential risks to individuals that fall on patients and science, data is central to our Introduction all areas of our business. As such we continue beyond the scope of existing laws. To mitigate mission to make meaningful improvements in to operate in strict adherence to these laws and these risks, we apply our key data ethical patients' lives. We are committed to handling regulations, while further enhancing our data principles: data ethically, respecting individuals' rights, privacy practices. and upholding societal values while ensuring • We ensure that the economic benefits of our compliance with relevant laws, regulations and work with data do not outbalance ethical Our comprehensive data privacy policies and guidelines. considerations. procedures mandate that both our employees and our business partners adhere to these strict • We only gather, process and retain data With recent advances in artificial intelligence, P|ESG standards. We support the security, accuracy as long as we have a legitimate business we are taking steps to integrate responsible Approach purpose. and transparency of personal data processing AI principles into our data governance. We by establishing clear protocols for collection, • We make sure that data is kept secure and are actively developing an AI framework that storage, use, transfer and disposal. shared in a way where individuals' rights are promotes transparent, ethical and safe use of AI protected. systems in alignment with our commitment to For any third-party data processing, we undertake data ethics. • We only use secure systems and processes thorough assessments to confirm that our when sharing or obtaining data from third business partners are equally committed to parties. Our long-term commitment is to continually safeguarding personal data. We implement Progress enhance our data ethics and AI awareness • We are transparent when we engage with data processing agreements as well as data programs, ensuring employees and partners those who have a legitimate stake in the transfer agreements (if relevant) to enforce data understand our standards when gathering, data we process, and we will inform and, protection, as well as regular monitoring to verify processing and managing data. We stress quality, where relevant, obtain consent from any compliance. integrity, transparency and security in data persons or legal entities. handling. Additionally, our data ethics standards • To the extent we leverage technologies like extend to third parties who work with data on our AI, we do this in a responsible manner. behalf. Ambitions See our full Data Ethics Policy in our Code of Business Conduct & Ethics. 32

Ascendis Pharma further displayed the Animal Welfare commitment to animal welfare by signing Animal studies are required by regulatory the Marseille Declaration on the worldwide authorities and play an important role in the implementation of high standards for animals development of new pharmaceuticals. The housed and used internally and externally by the Introduction Ascendis Pharma Internal Committee for Animal industry for scientific purposes . This declaration Welfare reinforces our continued commitment is a joint commitment statement by the to apply the best possible welfare for animals signatories to prioritize and request high animal used in the development of safe and effective welfare standards from CROs and suppliers. human treatments. Our principles reflect the Furthermore, it is a collaboration to improve 3R framework: Replacement, Reduction and animal welfare and health globally. Refinement. We emphasize the conduct of only necessary and scientifically sound animal studies, With the aim of increasing the company-wide P|ESG minimizing the use of animals in our research awareness of the work of the Committee, the Approach whenever possible. 3R principles and animal welfare initiatives in 2024, our Internal Committee for Animal Welfare All non-clinical studies conducted by Ascendis published articles on the company intranet, Pharma are performed at external Contract prepared training material to be included in the Research Organizations (CROs). These CROs are onboarding of employees and hosted an internal audited regularly for compliance with our high knowledge-sharing session with focus on animal standards for animal welfare in the housing welfare initiatives within the company. and care of experimental animals. In addition, Progress all animal study protocols are reviewed by the internal Committee for Animal Welfare ahead of signing to ensure consistent focus on animal welfare in the conduct of studies. To address animal welfare at suppliers of animal- derived biological matrices to Ascendis Pharma studies, comprehensive questionnaire-based Ambitions audits were conducted in 2024. The purpose was to identify suppliers that adhere to the same high standards of housing and care of animals as our approved CROs do, A vendor short-list of approved suppliers has been generated. 33

2024 and 2025 Sustainability and P|ESG Reporting Ambitions 2024 Ambitions Status Progress in 2024 2025 Ambitions Continuous enhancement of our current third- party compliance approach as well as further In Carried out due diligence on sales and Introduction development of the due diligence process for progress distribution partners. high-risk business partners. Further strengthen our Global Conduct a double materiality assessment, We conducted a pilot Double Materiality Compliance Framework. which will include KPIs to track in relation to our Ongoing Assessment (DMA) and continued improving our governance performance and identify key P|ESG methodology. Review our material governance priorities. impacts, risks and opportunities as part of our 2025 DMA. Ensure local implementation in new markets of Various policies and procedures have been Ongoing our Global Compliance Framework. implemented to support future launches. P|ESG Further strengthen our compliance Approach frameworks in our EU direct Expand animal welfare audits to include Relevant suppliers of biological matrices were markets to prepare for future suppliers of biological materials to ensure that identified across the organization and audited launches. Achieved they comply with the Ascendis Pharma global based on a detailed animal welfare questionnaire animal welfare standards. developed for this purpose. Generate an audit plan of vendors for biological matrices and initiate Establish an approved supplier list for animal Successfully established an approved supplier the conduct of on-site audits of matrices used in-house and at external contract Achieved list for animal matrices used in-house and at these vendors. laboratories. external contract laboratories. Progress Implement use of approved vendor list for biological matrices across Employees across the organization participated organization and at external in external and internal meetings and Increase internal awareness and knowledge of vendors. conferences to increase knowledge of NAMs Novel Approach Methodologies (NAMs) such as Achieved and subsequently initiated processes to identify in silico, in vitro and ex vivo approaches. relevant in silico, in vitro and ex vivo methods for implementation. Ambitions 34

2025 Sustainability & P|ESG Ambitions In 2025, we will further align our Sustainability & P|ESG framework to upcoming regulations by completing our Double Materiality Assessment to identify P|ESG impacts, risks and opportunities in our operations and value chain, and integrating our Sustainability Statement in our Annual Report. Introduction Patients Environmental • Monitor the regulatory • Review the material environmental impacts, risks and opportunities within our commercial landscape and seek input from supply chains, as part of our 2025 DMA. industry peers and patient advocacy groups on the developing field of population P|ESG Social Approach diversity in clinical trials with specific focus on rare diseases, • Attraction, onboarding and retention of talent to ensure we have the right people to deliver on including oncology. our ambitions. • Establish access pathways • Continuous focus on leadership and employeeship development to enable the development, to our entire endocrinology performance and well-being of our people. portfolio across the world to all patients in need. • Investigation of our pay policies, emphasizing pay equity across the organization and taking Progress actionable steps towards ensuring a clear, objective and transparent pay approach. • Add innovative technology based on TransCon to the HCPs' armamentarium, Governance establishing it as the gold standard of care for treating rare endocrine diseases. • Further strengthen our Compliance Program. • Champion ethical, meaningful • Further strengthen our compliance frameworks in our EU direct markets to prepare for future and evidence-driven scientific launches. Ambitions exchange with HCPs, anchored • Generate an audit plan of vendors for biological matrices and initiate the conduct of on-site in our deep knowledge of audits of these vendors. medical science, to improve outcomes in individuals with • Implement use of approved vendor list for biological matrices across organization and at rare diseases. external vendors. 35

This report may contain forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, ob- jectives and expectations for our business operations and financial performance and condition, including with relation to our sustainability efforts. Any state- Introduction ments contained herein that are not statements of historical facts may be deemed to be forward-look- ing statements. In some cases, you can identify forward-looking statements by terminology such as aim , believe , continue , commit , dedicate , ensure , could , due , estimate , expect , goal , may , objective , plan , potential , positioned , seek , should , target , will , would and other P|ESG similar expressions that are predictions or indicate Approach future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include our plans for 2023 and onwards with respect to our Sustainability and P|ESG strategy and ambitions. These forward-look- ing statements are based on senior management's current expectations, estimates, forecasts and projec- tions about our business and the industry in which Progress we operate and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this report may turn out to be inaccurate, perhaps materially so. The for- ward-looking statements speak only as of the date of this report. Except as required by law, we assume no obligation to update or revise these forward-looking Ambitions statements for any reason, even if new information becomes available in the future. Given these risks and uncertainties, you are cautioned not to rely on such forward-looking statements as predictions of future events. 36

Ascendis® Ascendis Pharma A/S (Company Reg. No. 29918791) Tuborg Boulevard 12 2900 Hellerup Denmark Tel: +45 70 22 22 44 Ascendis, Ascendis Pharma, Ascendis Pharma logo, the company logo, Skytrofa, Yorvipath, Ascendis Signature Access Program and TransCon are trademarks owned by the Ascendis Pharma Group. ©Ascendis Pharma A/S. April 2025. Version 1.0